N30 makes new board appointment
This article was originally published in Scrip
Dr Joseph Loscalzo has joined the board of N30 Pharma, the US cardiopulmonary medicine company focused on the modulation of endogenous nitric oxide bioavailability using targeted small-molecule drugs. He will also chair the company's scientific advisory board. Dr Loscalzo currently serves as the Hersey Professor of Theory and Practice of Medicine at Harvard, as Physician in Chief at Brigham and Women's Hospital and as editor in chief of Circulation.